Risankizumab for Eczema: Two Numerical Advantages Did Not Meet the Trial’s Primary Endpoint

November 9, 2026

Dr. Arsy #003 white 4 oz (120 g) jar beside golf equipment on a clubhouse bench; AI-created editorial illustration.

DOCTOR’S NOTES · ECZEMA EVIDENCE

A numerical treatment advantage is not automatically a statistically established benefit. A phase 2 risankizumab eczema trial provides two clear examples, while also showing why later endpoints cannot rescue a missed primary comparison.

Who was randomized?

The 2023 primary paper reports 172 participants aged 12 or older with moderate-to-severe atopic dermatitis. Sixty-nine were assigned to each risankizumab dose group and 34 to placebo. The first treatment period lasted 16 weeks. The primary endpoint was EASI75: at least a 75% reduction in the skin-severity score, rather than complete clearance or freedom from itch.

Comparison at week 16	Reported EASI75 difference versus placebo
150-mg group	13.0 percentage points; 95% CI −1.7 to 27.7; P=.084.
300-mg group	10.0 percentage points; 95% CI −4.6 to 24.6; P=.179.
Primary conclusion	Neither dose established a significant advantage on the primary endpoint.

Read a difference as a difference

The 13-point estimate is a difference between response proportions, not a statement that an individual’s eczema improved by 13%. Its interval crosses zero. That means these data do not establish a positive difference with the stated level of confidence. The same issue applies to the 10-point estimate for the higher dose.

The study specified statistical rules for its two dose comparisons and ranked endpoints. P=.084 should not be described as a positive result by rounding it down, calling it nearly significant or replacing it with the fact that some participants improved. A trial can contain real improvements in individuals without establishing that the drug produced an advantage over placebo.

Why secondary outcomes need restraint

The authors explicitly state that the testing hierarchy was interrupted after the primary step. Consequently, other efficacy endpoints cannot be claimed statistically significant under that planned hierarchy. A selected clearance or itch result should not be promoted as a confirmed success while the primary finding disappears from the summary.

A later 36-week treatment period was planned, with placebo recipients switching to active treatment. However, the study was terminated after the primary analysis and the reported efficacy focuses on the first period. A planned year of treatment is not the same as a completed, year-long placebo-controlled efficacy demonstration.

Keep safety and sponsorship attached

The paper reports that most adverse events were mild or moderate. It also reports serious adverse events in five risankizumab recipients, including two cellulitis cases. Those observations must remain visible alongside the authors’ overall tolerability assessment. Event occurrence alone does not establish causation, and a limited trial cannot establish freedom from uncommon harms.

AbbVie funded the study and participated in design, data collection, analysis, interpretation and publication. Several authors were company employees. These disclosures provide context for evaluating the evidence; they do not change the prespecified endpoint result.

A useful question before extrapolating

Ask whether the evidence concerns the condition you actually have. A biological pathway’s role in one inflammatory disease does not guarantee the same treatment response in eczema. This article evaluates this eczema trial and does not advise changing a medicine prescribed for another diagnosis.

If daily care is still failing around work, sleep or exercise, review the diagnosis, outcomes and treatment options with the clinician overseeing care. Our ligelizumab trial explanation examines another example of why a plausible immune target needs its own clinical comparison.

Where daily moisture care fits

Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not the intervention in this research. These findings do not establish infant suitability or pediatric efficacy for #003. A child’s clinician can advise on appropriate moisture care.